Shares of Corcept Therapeutics Incorporated CORT were up a staggering 109.1% on March 31 after the company announced data from the phase III ROSELLA study, which evaluated its pipeline candidate ...

As of 10:09:27 AM EDT. Market Open. The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian cancer meets the primary endpoint.

Purpose-built tool connects web traffic to financial advisor intelligence, enabling asset managers to target RIAs more effectively ATLANTA, April 01, 2025--(BUSINESS WIRE)--AdvizorPro, a leading ...

$CORT insiders have traded $CORT stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.